GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (XTER:ILU) » Definitions » Cyclically Adjusted Revenue per Share

Illumina (XTER:ILU) Cyclically Adjusted Revenue per Share : €24.13 (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Illumina Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Illumina's adjusted revenue per share for the three months ended in Sep. 2024 was €6.082. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €24.13 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Illumina's average Cyclically Adjusted Revenue Growth Rate was 7.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 17.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Illumina was 33.20% per year. The lowest was 14.90% per year. And the median was 19.30% per year.

As of today (2025-01-18), Illumina's current stock price is €134.64. Illumina's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was €24.13. Illumina's Cyclically Adjusted PS Ratio of today is 5.58.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Illumina was 32.69. The lowest was 3.65. And the median was 19.23.


Illumina Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Illumina's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Cyclically Adjusted Revenue per Share Chart

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.47 13.58 17.59 21.37 23.45

Illumina Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.89 23.45 24.43 25.66 24.13

Competitive Comparison of Illumina's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Illumina's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Illumina's Cyclically Adjusted PS Ratio falls into.



Illumina Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Illumina's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=6.082/133.0289*133.0289
=6.082

Current CPI (Sep. 2024) = 133.0289.

Illumina Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 2.795 99.070 3.753
201503 3.347 99.621 4.469
201506 3.226 100.684 4.262
201509 3.276 100.392 4.341
201512 3.654 99.792 4.871
201603 3.471 100.470 4.596
201606 3.608 101.688 4.720
201609 3.654 101.861 4.772
201612 3.965 101.863 5.178
201703 3.804 102.862 4.920
201706 4.008 103.349 5.159
201709 4.048 104.136 5.171
201712 4.436 104.011 5.674
201803 4.285 105.290 5.414
201806 4.801 106.317 6.007
201809 4.906 106.507 6.128
201812 5.014 105.998 6.293
201903 5.025 107.251 6.233
201906 4.977 108.070 6.126
201909 5.565 108.329 6.834
201912 5.750 108.420 7.055
202003 5.253 108.902 6.417
202006 3.798 108.767 4.645
202009 4.555 109.815 5.518
202012 5.293 109.897 6.407
202103 6.246 111.754 7.435
202106 6.358 114.631 7.378
202109 6.156 115.734 7.076
202112 6.759 117.630 7.644
202203 6.984 121.301 7.659
202206 7.002 125.017 7.451
202209 7.173 125.227 7.620
202212 6.512 125.222 6.918
202303 6.426 127.348 6.713
202306 6.870 128.729 7.099
202309 6.636 129.860 6.798
202312 6.512 129.419 6.694
202403 6.226 131.776 6.285
202406 6.497 132.554 6.520
202409 6.082 133.029 6.082

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Illumina  (XTER:ILU) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Illumina's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=134.64/24.13
=5.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Illumina was 32.69. The lowest was 3.65. And the median was 19.23.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Illumina Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Illumina's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina Business Description

Industry
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina Headlines

No Headlines